Madrid, June, 2024 – In a distinguished ceremony held at the Spanish Royal National Academy of Pharmacy (Real Academia Nacional de Farmacia), Professor Jose Luis Pedraz Muñoz, a prominent figure at the University of the Basque Country, was officially inducted as an “Académico de Número”. The highest position within the Royal National Academy of Pharmacy.
Professor Pedraz, who is also a member of the CIBER-BBN and Director of Unit 10 of NANBIOSIS, took possession of “Medal Number 16”. The honor of becoming an “Académico de Número” is a prestigious recognition, from which there can only be a maximum of 50 members at a time. This acknowledes Professor Pedraz’s significant contributions to the field of pharmaceutical technology. During the event, he delivered an insightful speech titled “3D Printing and Bioprinting in Pharmaceutical Technology.”
3D bioprinting, the future of Pharma
Prof. Pedraz’s speech highlighted one of his most pioneering research areas, 3D printing and bioprinting. Together with his research group, NanoBioCel, Prof. Pedraz leads this field with new cutting-edge initiatives.
This innovative lab, which services are channeled through our Unit 10, offers bioprinting services that enable the creation of three-dimensional structures of organs and tissues, new pharmaceutical forms, micro/nano vesicles, and scaffolding for regenative medicine, to name a few.
This recognition by the Royal National Academy of Pharmacy is not just a personal achievement for Professor Pedraz. It is also a testament to the innovative work being done within NANBIOSIS and CIBER-BBN. His contributions are paving the way for future advancements in pharmaceutical and biomedical research, reinforcing the importance of interdisciplinary collaboration and technological innovation in improving healthcare outcomes.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
